No End In Sight: Pharma Companies Continue To Face Government Probes
You may also be interested in...
FDA leaves door open to modify label of Amarin’s omega-3 fatty acid therapy Vascepa prior to approval in a healthier population, says company CEO. Per the current label, triglycerides are lowered significantly with no increase in LDL cholesterol, a potential differentiating point from Pronova/Glaxo’s blockbuster EPA/DHA therapy Lovaza.
An open letter to the “health care community” from a bipartisan group of senators on the Finance Committee asks for white papers offering suggestions on the best ways to combat “the multi-billion dollar problem” of waste, fraud and abuse in Medicare and Medicaid.
“There are enough layoffs out there that there is this walking group of disaffected people who are continuing to file qui tams, whether those are valid or not,” Boston Assistant U.S. Attorney Susan Winkler says. A Pfizer attorney suggests proactive steps to protect corporate leaders from prosecution.